{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:50:23Z","timestamp":1789159823966,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clml.2018.08.015","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T12:50:28Z","timestamp":1535547028000},"page":"829-835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Gwynivere A.","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle H.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea C.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.08.015_bib1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib2","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial","volume":"16","author":"Solal-C\u00e9ligny","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib3","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2018.08.015_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.015_bib5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib7","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-C\u00e9ligny","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjh.13895","article-title":"Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era","volume":"172","author":"Nastoupil","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.015_bib9","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.015_bib10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3109\/10428194.2014.953144","article-title":"Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States","volume":"56","author":"Nastoupil","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.08.015_bib11","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.015_bib12","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib13","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.015_bib15","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.015_bib16","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib18","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","article-title":"Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis","volume":"121","author":"Prica","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.08.015_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjh.13316","article-title":"A\u00a0population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait","volume":"169","author":"El-Galaly","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.015_bib20","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.015_bib22","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","article-title":"Guidelines on the investigation and management of follicular lymphoma","volume":"156","author":"McNamara","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.015_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clml.2014.07.015","article-title":"A\u00a0Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board","volume":"15","author":"Kuruvilla","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 5","key":"10.1016\/j.clml.2018.08.015_bib25","first-page":"v83","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.23372","article-title":"SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma","volume":"88","author":"Zinzani","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.08.015_bib27","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.015_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M","article-title":"An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute","volume":"52","author":"Garvin","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.08.015_bib30","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume":"23","author":"Colombat","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib31","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.015_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2018.08.015_bib33","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00277-016-2800-1","article-title":"Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era","volume":"95","author":"Yuda","year":"2016","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018304531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018304531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:20Z","timestamp":1761870680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018304531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S2152265018304531"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}